Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan.
about
Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.Telmisartan suppresses cardiac hypertrophy by inhibiting cardiomyocyte apoptosis via the NFAT/ANP/BNP signaling pathwayEffects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.Pre-clinical and clinical experience of telmisartan in cardiac remodelling.Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan.Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension.Treatment-associated change in apelin concentration in patients with hypertension and its relationship with left ventricular diastolic function.Diagnosis and management of left ventricular diastolic dysfunction in the hypertensive patient.Telmisartan: a review of its use in cardiovascular disease prevention.Telmisartan: just an antihypertensive agent? A literature review.Diastolic heart failure in dialysis patients: mechanisms, diagnostic approach, and treatment.Left Ventricular Diastolic Dysfunction in End-Stage Kidney Disease: Pathogenesis, Diagnosis, and Treatment.Aging and the brain renin-angiotensin system: relevance to age-related decline in cardiac function.Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial.Possible mechanisms of left ventricular torsion evaluated by cardioreparative effects of telmisartan in patients with hypertension.Effect of 24-week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene.Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension.Pharmacotherapy Choice Is Associated with 2-Year Mortality for Patients with Heart Failure and Reduced Ejection Fraction.
P2860
Q26773120-84BFEB7B-D595-4D5E-B9B8-A075904D3BABQ33672325-757E707D-6F4D-4A76-975E-1EC69D4BDF6BQ33791046-79C04D24-50D6-4FE8-BCB4-B876AB4EE182Q36285372-C3A9AA48-E72A-4B9F-8D49-A4DAADD44F72Q36541439-D0144E6B-9CA5-4E17-993D-A04273DD4238Q36642651-741948FA-70B7-43F1-BFBF-7490A267629EQ37201615-2AD40614-536B-4657-894D-C379EC64AA2DQ37680306-59DBE9D4-6760-4F62-80A4-61B486AD5F28Q37821746-D4414F5D-94AA-4D43-AF50-5C65ECB1B1B3Q37866755-9F923999-9796-4636-A1AD-2025D856694EQ37955284-3DFB749A-2E9C-4E6A-84D2-384245CD186DQ37978426-8139DCF1-314F-4630-9D31-88371A70D310Q38444264-F2587BF6-C7B5-49A8-8484-4E44D7D7F90DQ40097869-4ABD15FD-57DB-4F2D-9A69-DF3A3688A151Q42646839-5E080C7B-B498-4CE5-92D1-AAF97E2D4371Q43103664-7433ABB3-7E0A-4792-9757-DAA3DE23CCFBQ46750954-828CD49D-C1E7-4B14-8494-9834A5BAACB4Q46781548-E4E3364F-6D9D-4D5A-89FB-66D7617412AEQ47614022-D83AD4B3-EE4D-4716-97C1-9BAAE22A46B2
P2860
Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Regression of left ventricular ...... ents treated with telmisartan.
@en
Regression of left ventricular ...... ents treated with telmisartan.
@nl
type
label
Regression of left ventricular ...... ents treated with telmisartan.
@en
Regression of left ventricular ...... ents treated with telmisartan.
@nl
prefLabel
Regression of left ventricular ...... ents treated with telmisartan.
@en
Regression of left ventricular ...... ents treated with telmisartan.
@nl
P2093
P1476
Regression of left ventricular ...... ents treated with telmisartan.
@en
P2093
A V Mattioli
G Mattioli
P304
P356
10.1016/J.IJCARD.2003.10.018
P407
P577
2004-12-01T00:00:00Z